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I. INTRODUCTION

S
EVERAL precautions should be taken in using pharmaceutical drugs, for both healthcare professionals, who prescribe and administer drugs, and for drug consumers. Factors such as interactions among the prescribed drugs, interactions with the patient's current medication, side effects to be avoided, and contraindications, need to be carefully considered. Additionally, the presence of some drug properties, such as side effects and effectiveness, depends on characteristics of patients, such as age, gender, lifestyles, and genetic profiles. Having to consider all these complicated factors can be a huge burden to professionals and drug consumers.
In this work, our goal is to provide a tool to assist professionals and consumers in finding and choosing drugs. To achieve this goal, we develop an approach that allows a user to query for drugs that satisfy a set of conditions based on drug properties, such as drug indications, side effects, and drug interactions, and also takes into account patient profiles. For example, for an elder female patient with diabetes and epilepsy who is taking the medicines Enoxaparin and Aspirin, a query can be: Find a drug for diabetes and a drug for epilepsy that do not interact with Enoxaparin and Aspirin and do not interact with each other, for a female patient, age 60.
In order to answer drug queries, it is important that we have comprehensive drug information. Currently, there are several drug information sources that are open to public, such as DrugBank [2] , SIDER2 [3] , and KEGG Drug [4] . As these data sources offer different facets of drug information and have different coverage of drugs, we can combine data from these sources into a unified drug information base. However, it is nontrivial to use these data to answer drug queries effectively. Many of the data sources are manually curated and therefore have limited coverage. Some data sources contain information automatically extracted from text resources, such as drug labels and published articles, which may be prone to errors. Furthermore, many properties of drugs may not have been discovered. For example, long-time side effects of drugs may not be observed during clinical studies. Our challenge is to be able to provide good answers to the queries despite the incompleteness and the noisiness of data.
Considering the characteristics of drug data, traditional query systems that provide only the answers that exactly match the queries have several disadvantages. First, these systems can miss some answers that in fact can satisfy a query but do not exactly match the query due to the imperfection of the data. Second, by disregarding the possibility of incomplete information, the answers returned can be misleading. For example, if a query asks for a drug that does not interact with a particular drug, some of the drugs that interact with the given drug may also be given as answers because their interaction data are incomplete. Third, in the case that there are indeed no drugs that can satisfy a query, these systems do not return any answer to users, while offering answers that almost or partly satisfy the query could be helpful for the users to make further decisions.
To address the aforementioned problems, we propose an approach that considers not only the answers that exactly match the query but also those that closely match the query. We model the problem of answering queries as a subgraph matching problem, in which drug information is represented as a heterogeneous graph and a query is represented as a query graph. Then, we propose a score function for evaluating the quality of answers based on how well they match with a query graph. As a result, the incompleteness of data is explicitly taken into account.
The key contributions of this paper are as follows. 1) We propose an approach for answering drug queries. The approach considers both exact-and close-match answers to provide useful answers despite incomplete and noisy underlying datasets. Additionally, the answers are personalized based on a given patient profile. 2) We propose a score function for ranking the answers.
The score function estimates the likelihood of association between drugs and drug properties and integrates the likelihood to score an answer. 3) We propose an approach that leverages the network structure and the heterogeneity of the drug information graph to quantify edge likelihood in the graph. The approach outperforms a state-of-the-art approach that relies on finegrained drug properties, with up to 18% increase of overall AUROC (area under receiver operating characteristic) [5] and up to 37% increase of AUROC for drug properties with small positive training data. 4) We develop a prototype of the drug query system and demonstrate the benefits provided by our system through several example queries. The rest of this paper is organized as follows. We discuss related work in Section II. Section III provides our problem definition. Our methodology is presented in Section IV. In Section V, we describe how our approach personalizes answers for specific patient profiles. Section VI describes our prototype system. Section VII presents the evaluation of our approach. The conclusion is in Section VIII.
II. RELATED WORK
There are multiple drug information databases available for public access, such as DrugBank [2] , KEGG DRUG [4] , and PharmGKB [6] . Our work leverages these databases in order to provide a decision support tool for medical practitioners and drug consumers. A few studies aim to answer medical questions, including drug-related questions, and provide decision support on drug prescription [7] - [10] . These works model drug information as a relational database or an RDF (resource description framework) knowledge base. Their focus is on how to convert raw data into the knowledge base and how to translate questions in natural languages to SQL queries or SPARQL, a query language for RDF, in order to retrieve the answers. Our work is orthogonal to these existing works. We focus on providing high quality and useful answers to users despite the incompleteness and noisiness of available data. Our approach can be used together with the existing works to build a complete drug query system.
Several works have proposed techniques for answering queries over noisy data [11] - [14] . In these works, data are represented as a graph and answering queries is equivalent to finding subgraphs that match a given query graph. To handle data noisiness, for a given subgraph query, they return both similar and exact matches based on a similarity measure. Inspired by these techniques, our method represents drug information as a graph and defines a similarity measure specifically for drug queries, which incorporates the likelihood of associations between drugs and drug properties.
There are recent works on predicting drug properties (including drug targets, indications, and adverse effects), which are related to our problem of quantifying the association likelihood between drugs and drug properties. Network-based approaches have been proposed to discover novel drug-target interactions [15] - [17] , drug-drug interactions [18] - [20] , and drug adverse reactions [21] . In these approaches, networks containing drugs and drug property entities are created, and the network features, such as common neighbors or the number of paths, are used to predict drug properties. These existing studies have demonstrated that network structures can be used to effectively predict drug properties. However, in these existing approaches, the networks usually contain limited types of drug properties, while it has been shown that various kinds of drug properties are potentially useful for predicting a certain type of drug property [22] - [26] . Building on these existing works, we quantify the likelihood of drug properties based on the structure of a heterogeneous drug information network, which contains various types of drug property entities, including targets, pathways, chemical substructures, side effects, indications, and drug interactions. Our approach is extensible to include other types of drug properties as more information is available.
III. PROBLEM DESCRIPTION
We represent drug information aggregated from multiple data sources as a heterogeneous graph, i.e., a graph that has nodes of multiple types. Using the drug graph as a basis, we model the problem of answering queries as a subgraph matching problem.
A. Drug Graph Schema
Drug information is represented by a graph G(V G , E G , type G , key G ), where V G is a set of nodes and E G is a set of edges. Each node in the graph represents an entity of a specific type, which is either a drug (D) or a type of drug properties, such as a pathway associated with a drug (P), a target protein of a drug (T), an indication of a drug (I), a side effect of a drug (SE), and a chemical substructure of a drug (CH). type G is a function that maps a node to a node type. key G is a function that maps a node to a set of keywords related to the nodes, including identifiers and all the synonyms describing the node. For example, a node v that represents a drug has type G (v) = "Drug," and key G (v) includes the drug's generic names and brand names. Note that since each node has a specific type, a symptom (e.g., fever), which can be either a side effect or an indication, is represented as two distinct nodes in the drug graph.
The schema of the drug graph is shown in Fig. 1(a) . An edge from a drug to a drug property node (a node of type P, T, I, SE, or CH) represents the fact that the drug has or is associated with the particular property. An edge between two drug nodes represents the fact that the two drugs can interact.
B. Query Expression
Now we describe queries on the drug graph. A query is represented as a graph Q(V Q , E Q , type Q , key Q ). We refer to nodes in the query graph as query nodes. The query graph follows the same schema as the drug graph. There are two groups of query nodes. 1) Variable node: A variable node represents the information the user wants to find. The keywords of the variable nodes are not given in the query. 2) Reference node: A reference node serves as a reference for identifying the variable nodes. Each reference node has a keyword specified by a user.
Each edge in the query graph has a sign, which can either be positive or negative. A positive edge means that the user wants the connection to exist between the two nodes, while a negative edge means there should be no connection between the two nodes.
We show an example of a query graph in Fig. 1 (b). The query graph corresponds to the query: Find a drug for fever and allergy that does not interact with Enoxaparin and does not cause drowsiness and nausea. In this query graph, there is one variable node d 1 representing the drug to find. The drug d 1 is connected to the two indications with positive edges. To avoid side effects and interactions, negative edges are used to connect d 1 to the side effect nodes and another drug node.
C. Answering Drug Queries
Given a drug graph and a query graph, answering query is to find a subgraph in the drug graph that matches the query graph. We formally define an answer to a query as follows. An answer of a query Q(V Q , E Q , type Q , key Q ) is in the form of a mapping function f that maps each query node to a node in the drug graph such that: 1) For each variable node q v ,
Traditional query systems find exact answers for a given query, which are defined as follows. An exact answer is an answer f that satisfies the following properties: 1) For each positive edge e(q i , q j ) in E Q , there is an edge e(f (q i ), f(q j )) in the drug graph. 2) For each negative edge e(q i , q j ) in E Q , there is no edge between f (q i ) and f (q j ) in the drug graph. In this work, to cope with data incompleteness, we consider both the answers that exactly match the query graph and those that closely match the query graph. Therefore, the main problems we address are as follows: 1) How to assign a score to an answer to quantify how well it matches the query? 2) How to find the top-k answers with the highest scores to present to the users? We present our solutions to these problems in the next section.
IV. METHODOLOGY
In this section, we describe how we design a score function to evaluate the answers and present our algorithm for finding the top-k answers with highest scores. To simplify the explanation, the solution presented in this section does not take into account patient profiles. We discuss how to extend the approach to provide personalization in Section V.
A. Design of the Score Function
Because the drug information graph is incomplete, having no edge between a drug node and a drug property node does not necessarily mean that there is no association between the node pair. Taking this fact into consideration, our score function quantifies for each node pair the likelihood that there is an edge between the node pair and integrates the likelihood into the score of an answer. We first describe how to quantify the likelihood of an edge and then present the score function.
1) Quantifying Edge Likelihood: Several approaches for predicting drug properties have been proposed, which may be applied to quantify the edge likelihood between a drug and a drug property. Most of the approaches apply supervised machine learning techniques, using different feature sets to represent drugs. In these approaches, for each targeted drug property p, a classifier that determines whether a drug has the property p is trained using the drugs known to have property p as positive examples. A state-of-the-art approach proposed by Liu et al. uses chemical, biological, and phenotypic properties of drugs as drug features to predict drug side effects [27] . In this approach, each dimension of a drug feature vector is associated with a drug property p and has a binary value indicating whether the drug has the drug property p . We refer to this approach as the fine-grained-feature approach (FG).
While the FG approach has shown great potential in predicting drug properties, our experiments (Section VII) show that its performance degrades when the number of positive examples of the targeted drug property is small. This is a common problem when the feature vector is high-dimensional. To improve the predicting performance for drug properties with small positive samples, we propose a network-based approach, which uses summarized features instead of fine-grained features to represent drugs. a) Network-Based Approach. The network-based approach utilizes the structure of the drug information graph to create drug features. Intuitively, in the drug graph, two nodes that have many paths in-between should be closely related and more likely to have an edge between them. Thus, given a property node p, we can use the number of paths between the property p and a drug node to quantify the likelihood that the drug will have property p. However, simply using the number of paths may not be effective. Because the drug graph contains several types of nodes, the paths in the graph are representing different types of complex relationships. These complex relationships can have different importance in indicating whether there is an edge between a given node pair. Therefore, we differentiate the paths by path types and assign different importance levels to different path types. A type of a path is defined from the types of nodes along the path. For example, the path 2 , and se 1 are nodes in the drug graph, has the path type of D-T-D-SE, which represents the relationship where a drug shares a target with another drug that has a particular side effect. 
Our approach uses the closeness between a drug and a targeted drug property according to a path type m as a feature of the drug. To quantify the closeness between a drug d and a drug property node p with respect to a path type m, we consider two metrics.
1) Path count. In this metric, the number of type-m paths between d and p is used as their closeness. 2) Random walk. In this metric, the closeness of node d to node p is the probability of being at node d when we perform a random walk starting from node p, going along the paths of type m in reverse direction. Thus, for path type m with length l, we consider an l-step random walk. In each step, only a node of the type specified in m are considered. 
where β 0 , . . . , β l are the model parameters reflecting the importance of each path type. b) Learning Model Parameters. In this paper, our targeted edge types include drug-side effect, drug-indication, and drugdrug. The path types used for each type of edges are shown in Table I . For different types of edges, the importance of each path type can be different. Furthermore, even for the same edge type, the importance of path types could be different for each individual drug property. Therefore, we consider two schemes for parameter learning.
1) Per-type parameter learning: Learn one set of parameters for each edge type. 2) Per-node parameter learning: Learn one set of parameters for each property node. For example, with per-type learning, a single set of parameters is learned for the edge type drug-side effect; with per-node learning, one set of parameters is learned for each side effect.
We compare the performance of the two schemes in our experiments.
c) Hybrid Approach. Since our network-based approach uses summarized features, which is less informative than the finegrained features, when a targeted drug property has large positive training data, the FG approach could perform better. Therefore, we propose a hybrid approach that combines the FG approach and the network-based approach. In the hybrid approach, if a targeted drug property has more than τ known associated drugs, the FG approach is applied. Otherwise, the network-based approach is applied. We select τ to be 20 based on our experiments in Section VII.
2) Score Function for Query Answers: Based on our approach for quantifying the edge likelihood, we now define the score of an answer for a given query. Intuitively, in a good answer, the edges among the matches of the query nodes should correspond to the edges in the query graph. More specifically, if there is a positive edge between q i and q j , then there should be an edge between f (q i ) and f (q j ), the matches of q i and q j in an answer f . If there is a negative edge between q i and q j , then there should be no edges between f (q i ) and f (q j ). Our scoring function is defined based on this concept, as follows. 
where (1] . The function p is used to adjust the edge likelihood score to 1 if an edge already exists in the graph. The first product in S(f ) considers the edge likelihood between the node pairs connected by positive edges. The second product considers the complement of the edge likelihood, i.e., 1 − p(v i , v j ), for the node pairs connected by negative edges. The value of S(f ) ranges from 0 to 1. An answer f having S(f ) equal to 1 is an exact answer.
B. Finding the Top-k Answers
The algorithm for finding the top-k answers that have the highest scores consists of three steps. First, we find a set of candidate matches for each query node based on the keywords given in the query. Next, we compute the edge likelihood among the candidate matches, which will be used for computing the scores of the answers. This requires counting the number of paths or computing the random walk probability among the candidate nodes, as discussed in Section IV-A. Finally, we search for k answers that have the highest scores among all the answers, which are all the combinations of the query nodes' candidate matches. A branch-and-bound technique is applied to obtain the top answers quickly. For more details about our algorithm, we refer readers to [1] .
V. PERSONALIZING ANSWERS BASED ON PATIENT PROFILES
It is not uncommon that some drug properties are more common or present only in a patient with a specific profile. For example, the side effect vomiting for the drug Tamiflu is more common in children than adults [28] . In this section, we describe how to extend the approach in Section IV to use such information to personalize query answers.
A. Data Sources for Personalization
We assume that we have information on drug properties that are conditional on patient characteristics. While not much of such information are available yet, there are several data sources that can potentially be used to obtain such information. For example, the U.S. Food and Drug Administration (FDA) adverse event reports contain information on side effects of drugs experienced by a patient along with his/her information including age, gender, and weight.Another potential data sources are online communities, such as Facebook, Twitter, and health-related online message boards. Existing studies have shown promising results in using these resources to learn about side effects of drugs [29] - [37] . These online sources usually contain basic user profiles, such as age, gender, and location. Additionally, based on what people have expressed online, habits and lifestyles, such as being a vegetarian, smoking, or regular exercising, may be inferred. These data sources could allow future research to extract correlation between patient characteristics and drug properties.
From such data sources, we assume that we have a set of tuples T = {(v i , v j , A k , val)}, where v i is a drug node, v j is a drug property node, A k is a patient attribute, and val is a value of A k . Each tuple (v i , v j , A k , val) indicates that a drug v i exhibits a property v j for a patient whose attribute A k is equal to val.
B. Patient Profiles
A patient profile is used to describe a patient. Let A 1 , . . . , A n be all the attributes presented in T . We represent a patient profile as a vector A of size n, where A[i] is a value corresponding to attribute A i of the patient. We assume that the domain of each attribute is categorical. Attributes that are originally numerical can be transformed to categorical by grouping into ranges. For example, age can be divided into four ranges: child (age 0-12), teenage (age [13] [14] [15] [16] [17] [18] [19] , adult (age 20-64), and elder (age 65 and up).
C. Personalizing Answers
To provide personalized answers for a query with patient profile A, we create a personalized drug graph, G A , that contains information about drug properties with respect to the profile A. Let G represent a core drug graph, containing relationships between drugs and drug properties that do not rely on patient characteristics. G A is constructed by using data from T to modify the edges in G. Initially, we let G A contains all the nodes and edges in G. Then, for each tuple v j ) is added to G A . By using G A Fig. 2 . Drug query system. instead of the core graph, the approach described in Section IV can be applied to obtain personalized answers.
D. Case Study: Personalization on Side Effects of Drugs
As a case study, we describe how we personalize the answers on side effects of drugs. We use FDA adverse event reports as a side effect personalization data source. Each report contains the information about a patient (age, gender, and weight), the list of drugs taken by the patient, and the side effects of the drugs. The reports are submitted by both healthcare professionals and consumers. Although we cannot conclude that the drugs in each report are the causes of the side effects, the reports provide signals of potential associations between side effects and drugs for different patient profiles.
Our core drug graph contains only the associations between drugs and side effects that are common for all patients, for example, those extracted from drug labels. Using the reports, we add a tuple (d, se, A, val) to T if there are at least T reports that indicate a patient with attribute A = val has experienced the side effect se when using the drug d, where T is a threshold value. We focus on two patient attributes, age and gender. As mentioned earlier, age is grouped into four ranges. We refer readers to [38] for details on how much data from FDA reports can augment our core drug graph.
E. Case Study: Personalization With Biomarker Data
Genetic traits in patients can effect drug effectiveness and side effects. Some drugs are designed for treating diseases with specific biomarkers. To include this information in our query system, we use the table of drug pharmacogenomic biomarkers provided by FDA. 1 By manually going through the drug labels, we obtain 98 personalized tuples from this data source and add them to T . These tuples include drug indications that are specific to a particular biomarker and side effects that are introduced if patients have specific biomarkers.
VI. DRUG QUERY SYSTEM PROTOTYPE
In this section, we describe the drug query system prototype that we have developed. The overview of the drug query system is shown in Fig. 2 . There are four main components: drug information base, query processor, query translator, and user interface. The user interface accepts a drug query from a user and displays the answers obtained from the query processor to the user. The query translator is responsible for translating an input query, which is in a user-friendly format, to its corresponding query graph. It utilizes the MedDRA 2 dictionary to match synonyms of indications and side effects to reference nodes. The query processor computes the answers for the query graph using the algorithm we have described.
The user interface of the system is shown in Fig. 3 . The user interface provides a form for the user to input the conditions for the drug query in terms of drug indications, side effects, and drug interactions, along with a patient profile (No. 1 in Fig. 3 ). For each type of conditions, the user can input keywords, each of which will be mapped to nodes in the drug information graph by the query translator. The answers of a query and their scores are shown in a result table (see No. 2 in Fig. 3) .
Considering the subjective nature of the drug queries, to help users find the answers that best suit their needs, we provide two additional features: score component visualizer and condition weight adjustment.
1) Score Component Visualizer:
A score component visualizer (see No. 3 in Fig. 3 ) displays how well an answer can satisfy each of the conditions in the query. The condition scores are color-coded to allow users to quickly see the overview of the results. For example, in Fig. 3 , the user queries for a drug for headache and a drug for diarrhea without the sleepiness side effect and without drug interaction with Carboplatin. The sixth column in the score component visualizer corresponds to whether the second drug in an answer has the sleepiness side effect. By scanning the column, the user can quickly see that the second and third answers are likely to cause sleepiness. If sleepiness needs to be strictly avoided, the user can decide to leave the drugs out of their options.
2) Condition Weight Adjustment: Condition weight adjustment allows user to increase the importance of some conditions in the query. By assigning higher weights to some conditions, the query processor will adjust the ranking of the answers to bias towards those that can better satisfy the conditions with high weights.
VII. EVALUATION
Our evaluation consists of two parts. First, we evaluate the quality of edge likelihood scores. Then, we evaluate our query system by showing examples of query results and discuss the benefits provided by our system.
A. Data Sources and Drug Graph Characteristics
We consolidate drug information from multiple data sources to create the drug graph for our prototype query system, DrugBank. [2] . From DrugBank, we obtain information on drug targets, drug interactions, and chemical substructure signatures. The number of drugs in DrugBank is 7682. About 86% of the drugs have target information. About 15% of the drugs have the drug interaction information. [3] contains the information about side effects extracted from drug labels. There are 2021 drugs in SIDER2. About 49% of the drugs have side effect information.
KEGG Drug [4] . From the KEGG database, we obtain the information on the associated biological pathways of the drugs. There are 9354 drugs in the database. About27% of the drug have pathway information.
NDF-RT [39] . We use the relationships between drugs and diseases (indications) extracted from NDF-RT by Wang et al. [40] . The dataset contains 799 drugs and 719 diseases.
From the above data sources, we create the core drug graph. For side-effect and indication nodes, we assign their keywords based on MedDRA 3 preferred terms. The resulting graph contains 16 565 nodes and 256 447 edges. The numbers of nodes and edges of each type are shown in Table II . To create a personalized graph, we use the adverse drug event reports and the biomarker data from drug labels, provided by FDA, as described in Section V.
B. Evaluation of Edge Likelihood Quantification
Edge likelihood scores are the basis for computing the scores of the answers. The accuracy of the likelihood scores directly affects the quality of the query answers. Therefore, it is important that the likelihood scores are good predictors of the existence of edges.
1) Evaluation Method:
We evaluate the edge likelihood scores obtained from six approaches: fine-grained-feature approach (FG), network-based approach with path count metric and per-node parameter learning (MP), network-based approach with path count metric and per-type parameter learning (MPG), network-based approach with random walk metric and per-node parameter learning (MP_RW), network-based approach with random walk metric and per-type parameter learning (MPG_RW), and hybrid approach (Hybrid), the combination of FG and MPG_RW.
For all of these approaches, we build logistic regression models by utilizing the Python package scikit-learn. 4 The evaluation is performed for three types of edges: drug-side effect (D-SE), drug-indication (D-I), and drug-drug (D-D). For each edge type t, we perform ten-fold crossvalidation. In each fold, 10% of the drugs are assigned as test drugs, used for evaluating the performance of the predictors. We use AUROC and AUCPR as the evaluation metrics. Both metrics are commonly used in machine learning. AUROC emphasizes on identifying both the positives and negatives correctly, while AUCPR focuses more on the per- formance of an approach in identifying true positives [41] . The value of AUROC and AUCPR is between 0 and 1. Table III shows the performance of the six edge likelihood prediction approaches. First, we compare FG, MP, and MP_RW. It can be seen that the MP approach has competitive performance with the FG approach. Each of them performs better than the other in some of the edge types. On the other hand, the MP_RW approach significantly outperforms both the FG and MP approaches in terms of AU-ROC. It also performs better in terms of AUCPR for the D-I and D-D edges. These results show that the network-based features can potentially improve prediction performance and that the closeness metrics used in the network-based approaches can greatly affect the predicting performance.
2) Performance Comparison:
Next, we compare the two schemes of parameter learning in the network-based approaches. The results show that the approaches with per-type parameter learning tend to perform better than their per-node-learning counterparts (MP versus MPG and MP_RW versus MPG_RW). This illustrates the advantage of per-type parameter learning, where the positive samples from all the drug properties can be combined. Finally, it can be seen that the Hybrid approach has the best performance among all the six approaches. Comparing to the FG approach, the improvements in AUROC are 18%, 10%, and 15% for edge type D-SE, D-I, and D-D, respectively, and the improvements in AUCPR are 13%, 43%, and 15% for edge type D-SE, D-I, and D-D, respectively.
The above results may be counterintuitive in that the networkbased approaches have better performance than the FG approach despite using summarized features of drugs. To better understand why this is the case, we investigate the performance of the edge likelihood prediction approaches with varying numbers of positive training samples. For each property type (SE, I, D), we group the properties based on their numbers of positive training samples and report the prediction performance for each group. The result is shown in Fig. 4 .
From the figure, we observe that the network-based approaches outperform the FG approach when the number of training samples is small. The improvement is especially significant for drug properties with less than 20 positive training samples, where we can see the improvement in both AUROC and AUCPR. For such drug properties, compared to the FG approach, the MPG_RW approach improves the AUROC by 37%, 11%, and 21% and the AUCPR by 46%, 30%, and 43% for the edge type D-SE, D-I, and D-D, respectively. As the number of positive training samples becomes larger, the performance of the FG increases and finally overcomes the network-based approaches. For the MPG_RW approach, the FG approach requires 60 positive examples for each drug property to obtain better AUROC and 20 positive examples to obtain better AUCPR. Therefore, in the Hybrid approach, we set the threshold for switching prediction algorithms to be 20 positive samples.
In Fig. 5 , we show the percentage of drug properties in each group of training sample sizes. It can be seen that the majority of drug properties have less than 20 positive training samples. This explains why the overall performance of the network-based approaches is better than the FG approach (as in Table III) . Additionally, these results illustrate the benefit of the Hybrid approach, which selects the appropriate approaches to use based on the size of the positive training data.
C. Evaluation of Query Answering 1) Answer Quality:
We demonstrate the usefulness of our query system by showing examples of the query results returned from our system. First, we show the top results for the query [Query 1] "Find a drug for tonsillitis 5 " in Table IV . Our system finds both exact matches and close matches for this query. The top four answers have the highest possible score of 1. This means according to the drug information graph, these drugs are indicated for tonsillitis. The answers below the fourth place are inexact matches. According to the drug graph, these answers are not indicated for tonsillitis. However, by manually checking with external online data sources, we found supporting evidence that Cefaclor, Cefixime, Moxifloxacin, Cefprozil, and Levofloxacin (ranked from 5 to 9), may be used to treat tonsillitis [42] - [45] . For the tenth drug, Ceftazidime, although 5 An inflammation of tonsils caused by bacteria or virus infection. we cannot find references for its use in treating tonsillitis, it is also an antibacterial drug according to RxList. 6 This example illustrates that our approach can provide answers that exactly match the query as well as inexact matches that are potentially useful for users, which prt5ovides users with more alternatives.
Next, we consider the following query: [Query 2] "Find a drug for schizophrenia for the patient who is taking Paroxetine." In Table V , we compare the results from the approach that finds only exact matches with those from our approach. Using the exact-match approach, we obtain 13 drugs, with no ranking among these drugs. We manually checked drug interactions on external data sources, Drugs.com 7 and Medscape, 8 and found that in fact all drugs except Reserpine and Deserpidine can interact with Paroxetine. However, such interaction data are not contained in our drug interaction data source (DrugBank) and therefore the drugs are returned as answers. Using our approach, the returned answers receive varying scores, and the scores are less than one, indicating the possibility that they might interact with Paroxetine. Additionally, the two drugs that do not interact with Paroxetine according to our external data sources are ranked at the first place and the third place in our result list. This example demonstrates that by taking into account the likelihood of edges, our system is more informative and can help users to discover the drugs that fit their requirements better.
In the next example, we illustrate how the answers are personalized according to a given patient profile. We use the query: [Query 3] "Find a drug for schizophrenia without the side effect of cardiac arrest." We compare the top 15 results obtained when a user profile is not given and when the user profile is specified as {female, elder} in Table VI . When the user profile is given, Methotrimeprazine, Haloperidol, and Asenapine, are removed from the list. These three drugs were reported (via the FDA drug adverse event reporting system) as potential causes of cardiac arrest in elder female patients, and our approach takes into account this fact and adjusts the scores of the drugs accordingly. For more query examples, please refer to our technical report [38] .
2) Query Time: While the focus of this paper is on the quality of the answers, the response time of the drug query system is also important. With the current implementation, drug queries that look for a single drug with up to ten drug properties can be answered within a few seconds. For drug queries that ask for two or more drugs, the system takes from one minute to several minutes. In general, the query time increases with the number of drugs that are asked for and the number of conditions specified in the queries. To make the system more practical, the response time can be improved by adopting indexing and pruning algorithms and leveraging parallel and distributed computation [11] - [14] .
VIII. CONCLUSION
In this paper, we propose an approach for answering drug queries to support drug prescription. Our focus is on how to obtain and rank answers based on incomplete information and provide personalization. To cope with incomplete and noisy data, we allow both exact and close matches when answering queries. We also present an intuitive approach to display answers to users, which aims to help users to understand the ranked results and possibly refine their queries.
